The 2026-27 flu season is off to an early start, and the latest federal numbers show influenza climbing in many parts of the country even though overall activity is still labeled low. With the first pediatric death of the season now on the books, early November is a smart moment to get vaccinated and make a plan.
This is general information, not medical advice. Talk with your own clinician or pharmacist about your situation.
Where 2026-27 flu season activity stands right now
The most recent report we could verify is the CDC’s FluView report for week 42, ending October 24, 2026. It describes national flu activity as low but increasing in many parts of the country, and higher than is typical for this time of year. Here are the main figures:
| Measure (week ending Oct. 24) | What CDC reported |
|---|---|
| Clinical lab tests positive for flu | 7.6% (4,061 of 53,102 specimens) |
| Outpatient visits for flu-like illness | 2.4%, below the 2.9% national baseline |
| Lab-confirmed flu hospital admissions (NHSN) | 6,100 in the week, or 1.8 per 100,000 people |
| Estimated hospitalizations this season | At least 16,000 |
| Jurisdictions at “High” flu-like illness activity | 1 (up from none the week before) |
In plain terms, we are not in a peak yet. But the direction of travel is up, and the season began earlier than many people expect. Flu usually peaks in winter, so there is still time for the shot to protect you.
One virus is doing most of the work: H1N1
Among the 371 influenza A viruses that public health labs subtyped in week 42, 98.9% were A(H1N1)pdm09 and 1.1% were A(H3N2), according to the CDC report. Ten influenza B viruses were also reported.
That is a very lopsided mix. It is early, though, and the picture can shift as the season develops. Flu seasons can change character quickly, which is one reason health officials keep emphasizing preparation rather than prediction.
The first pediatric flu death of the season
CDC’s week 42 report lists one pediatric flu death for 2026-27, which occurred in week 40 and was associated with influenza A(H1N1). Contemporary Pediatrics reported that FluView does not include the child’s age, location or vaccination status.
The same article notes two local announcements. San Bernardino County, California, announced on October 30 the death of a child with underlying medical conditions who was too young to be vaccinated. County Health Officer Sharon Wang called it “a devastating reminder of how serious respiratory viruses can be.” Colorado also confirmed a pediatric flu death in mid-October, in an elementary school-aged child living outside the Denver metro area. It is unclear whether either case is the one counted nationally.
For context, the 2025-26 season’s pediatric death total now stands at 199 per the same CDC report. Every one of those is a family’s loss, and it is why pediatric groups push vaccination so consistently.
Flu vaccine effectiveness and strain concerns
Last season, an H3N2 variant called subclade K spread widely. The FDA’s advisory committee voted unanimously on March 12, 2026 to update the 2026-27 vaccines to target it, matching a World Health Organization recommendation, as Becker’s Hospital Review reported. According to CDC’s 2026-27 season page, all three vaccine components changed from last year, and the supply is entirely trivalent (three-strain). Manufacturers projected up to 135 million doses.
Early lab data look reassuring on match. In the week 42 report, CDC said 94.2% of tested H1N1 viruses were well recognized by antibodies to the vaccine reference virus. All 22 tested H3N2 viruses and all 33 tested B/Victoria viruses were also well recognized.
There is an important caveat. CDC says it is too early to determine what this means for vaccine effectiveness. A good lab match is encouraging, but real-world effectiveness estimates come later in the season. Even in years when the match is imperfect, vaccination is generally aimed at reducing the risk of illness and, especially, severe illness.
For the policy background, see our earlier explainers on the CDC’s interim flu vaccine guidance and on flu, COVID and RSV recommendations from medical groups.
What is the flu, and who is at higher risk?
Influenza is a contagious respiratory illness caused by flu viruses. It often arrives suddenly, with fever, cough, sore throat, body aches, headache and fatigue. It is different from a common cold, which tends to build more gradually and rarely causes high fever.
Anyone can get seriously ill, but CDC identifies certain groups as being at higher risk of complications. The agency’s treatment page names people with conditions such as asthma, diabetes or heart disease. CDC’s separate higher-risk page has the full list, which also includes young children, older adults and pregnant people. Infants under 6 months cannot be vaccinated themselves, so protecting the people around them matters.
What to do this week: a practical checklist
- Get your flu shot now if you have not. CDC says flu vaccines are available for everyone 6 months and older. Protection takes about two weeks to build, so earlier is better.
- Vaccinate kids. Children under 6 months cannot get the shot, so vaccinating household members and caregivers helps shield them.
- Ask about other vaccines. Flu, COVID-19 and RSV recommendations differ by age and health status. Our guide on the RSV vaccine and infant antibody covers that piece.
- Stay home when sick. Avoid work, school and gatherings while you have a fever, and wash hands often.
- Know your higher-risk status. If you or a family member has a chronic condition, decide in advance whom you would call if symptoms start.
- Call early, not late. If you have flu symptoms and are at higher risk, very sick or worried, CDC says to contact a health care provider right away.
Antivirals and when to seek care
Flu antivirals are prescription medicines and come as pills, liquid, an inhaled powder or an intravenous solution, according to CDC’s treatment guidance. They are usually not needed for healthy people at low risk of complications. CDC recommends early treatment for people with flu or suspected flu who are at higher risk, and says treatment may also be considered for people who are very sick, including those who are hospitalized.
Timing matters. Antivirals work best when started within two days (48 hours) of symptom onset, when they can lessen symptoms and shorten illness by about a day. Starting later can still help higher-risk or very sick patients. That is why waiting to see whether you improve can be a poor strategy if you are in a higher-risk group.
Seek urgent medical care for trouble breathing, symptoms that improve and then return with a worse fever or cough, confusion, dehydration, or any symptoms in an infant or medically fragile person that worry you. When in doubt, call your provider or local emergency number.
Why early-season numbers deserve attention
A week-to-week percentage can look small, but the trend is the story. Test positivity of 7.6% in late October, with hospital admissions already counted in the thousands, tells health officials that the virus is circulating in communities well before the holiday travel and indoor gatherings that typically fuel spread. Local conditions vary, so check your state or county health department for the most relevant picture.
Also remember that national reports lag. Death reports, in particular, can arrive weeks after the event, which is why counts can change from one FluView release to the next. We have not been able to verify any newer report than week 42 at the time of writing.
The bottom line
The 2026-27 flu season is early, H1N1-dominated so far, and still in its early climb. Early lab data suggest a good vaccine match, but effectiveness estimates are not yet in. The best move this week is simple: get vaccinated, protect babies and older relatives, and do not delay calling a clinician if you are at higher risk and get sick. We will update as new CDC reports are released.
